Alamar Biosciences (ALMR) 10% Owner Ltd. Sells $3.9M of Stock

Major shareholder Qiming Corporate GP VI, Ltd. sold 133,811 shares of Alamar Biosciences, Inc. (NasdaqGS: ALMR) on October 22, 2026. According to a Form 4 filed with the SEC, the shares were sold at an average price of $29.33, totaling roughly $3.9 million. The stock closed at $29.72 on the day of the transaction.

ALMR Alamar Biosciences, Inc.

$29.72 ▲ +18.31% past 3 months

1M 3M

Daily close · Oct 22, 2026

Inside Qiming Corporate GP VI, Ltd.'s Alamar Biosciences Trade

The latest transaction reduced the major owner's holdings by 6.96%, leaving the firm with 1,789,183 shares of Alamar Biosciences. This sale marks its fourth reported trim of stock in October 2026.

Other Institutional Activity in Alamar Biosciences

Other large institutional holders adjusted their positions earlier in the year. Sands Capital Alternatives, LLC grew its holdings by 2,115,463 shares, ending with 4,230,926 shares worth about $129,847,121. Samsara BioCapital, LLC grew its holdings by 1,240,155 shares, ending with 2,480,310 shares worth about $76,120,715. ARK Investment Management, LLC grew its holdings by 686,980 shares, ending with 1,373,959 shares worth about $42,166,802. Braidwell LP grew its holdings by 541,992 shares, ending with 1,083,983 shares worth about $33,267,438. Alliancebernstein L.P. grew its holdings by 501,538 shares, ending with 1,003,077 shares worth about $30,784,433.

Alamar Biosciences, Inc. Stock Down 2.4%

Alamar Biosciences shares recently traded around $30.69 as of October 24, 2026, sitting 3.3% above the event-day close and 15.0% above the 200-day moving average of $26.69.

Recent Earnings

Alamar Biosciences reported trailing-twelve-month revenue of $100,420,000 with a net margin of -49.5%. The company is scheduled to report its next round of financial results on November 3, 2026.

Insider Buying and Selling at Alamar Biosciences, Inc.

Prior to this transaction, Qiming Corporate GP VI, Ltd. sold 173,537 shares on October 15, 2026, for roughly $4.8 million, 75,508 shares on October 19, 2026, for about $2 million, and 142,004 shares on October 20, 2026. Earlier in the year, director Nicholas J. Naclerio bought 235,294 shares on April 20, 2026, for $5,176,468.

Analysts Set New Price Targets

Stifel and JP Morgan maintain positive ratings on Alamar Biosciences, with price targets ranging from $32.00 to $35.00 ahead of the upcoming earnings release.

About Alamar Biosciences

Alamar Biosciences, Inc. is a Fremont, California-based medical device company focused on proteomics. It develops the NULISA platform to help detect and quantify protein biomarkers for early disease detection.

Bottom Line

Investors will look toward Alamar Biosciences' upcoming earnings report on November 3, 2026, for updates on revenue growth and product adoption.